Revenue Growth
Total revenue of $216.5 million in Q1 2026, up ~2.2% year-over-year (from $211.8M in Q1 2025). Hospital division revenue grew to $207.6M (up 1.8% YoY) and same-hospital revenue was roughly flat (+0.2% YoY).
Net Income Improvement
Net income attributable to Nutex was $46.8 million versus $21.2 million in Q1 2025 — an increase of $25.6 million (approximately +121% year-over-year).
Strong Operating Cash Flow and Liquidity
Net cash provided by operating activities was $75.5 million in Q1 2026, up 48% from $51.0 million in Q1 2025. Cash and cash equivalents grew to $207.3 million as of March 31, 2026, up 11.7% from $185.6 million at year-end 2025.
Share Repurchase Activity
Completed inaugural $25 million share repurchase program retiring ~119,000 shares and initiated a second $25 million repurchase program during the quarter, signaling management confidence in intrinsic value.
Patient Volume and Engagement
Total hospital visits increased to ~49.7K (49,742 reported by CFO), up ~3.1% year-over-year. Same-hospital visits increased modestly (~+0.6%). Patient experience strong: over 2,400 reviews and average Google rating of 4.8/5.
Population Health Momentum
Population Health division revenue increased to $8.9 million in Q1 2026 from $7.8 million in Q1 2025 — ~+14% year-over-year; platform now oversees ~40,000 patients across Medicare Advantage, commercial and Medicaid managed care.
Balance Sheet Deleveraging and Asset Growth
Net long-term debt decreased from $29.2 million at Dec 31, 2025 to $24.3 million at quarter end. Total bank/equipment debt declined modestly (example: $41.3M at Mar 31, 2026 vs $43.5M at Dec 31, 2025).
Strategic Investment in Development and Technology
Board approved direct investment in development/construction of new hospitals (project cost ~$20–30M each; 18–24 month build timeline). Company plans to monetize via sale-leaseback/REIT transactions; ongoing investments in AI/IT and service lines to drive growth and scalability.
IDR / Arbitration Track Record
Company submits ~50–60% of claims through the IDR process, currently prevailing >85% of determinations and collecting >80% of awarded amounts — demonstrating effectiveness of arbitration strategy despite timing volatility.